Attorney General James Secures $720 Million Settlement from Opioid Manufacturers
New York Attorney General Letitia James announced today that eight pharmaceutical companies will pay a combined $720 million to settle claims related to their role in fueling the nation’s opioid crisis. New York State is set to receive up to $38.7 million from the settlement, which will be used to support opioid abatement, treatment, and prevention efforts across the state.
The settlement brings Attorney General James’ total recovery for New York from opioid-related lawsuits to more than $3 billion.
“For years, drug companies prioritized profits at the expense of struggling New Yorkers who became trapped in deadly opioid addictions,” said James. “These resources will help us begin to heal and ensure support reaches the communities most affected by the crisis.”
The eight companies and their settlement contributions are:
- Mylan (Viatris) – $284.4 million over 9 years
- Hikma – $95.8 million over 1–4 years
- Amneal – $71.7 million over 10 years
- Apotex – $63.7 million in one year
- Indivior – $38 million over 4 years
- Sun – $31 million over 1–4 years
- Alvogen – $18.7 million in one year
- Zydus – $14.9 million in one year
In addition to the financial settlement, the companies will contribute $14 million in supplemental funding and provide opioid addiction treatment medications or equivalent cash—valued at roughly $86 million. Four companies—Mylan, Hikma, Amneal, and Indivior—will be responsible for these treatment resources.
As part of the agreement:
- All companies except Indivior are barred from marketing or promoting opioid products.
- None may manufacture or sell pills containing more than 40 mg of oxycodone.
- All must implement systems to monitor and report suspicious orders.
- Indivior, while prohibited from selling or manufacturing opioids for the next decade, will continue to market medications used to treat opioid addiction.
Payments from the settlement are expected to begin in 2026.
